2012 7th Summit on Biosimilars and Follow-On Biologics
Summit - Washington, D.C., U.S.A.
Leverage the Regulatory, Legal and Clinical Realities of the Biologics Price Competition and Innovation Act to Achieve Maximum Commercial Value
The Patient Protection and Affordable Care Act of 2010 (PPACA) has opened a yet-unused pathway for biosimilars in the U.S. In November, stakeholders had the opportunity to voice their ideas on FDA’s implementation of this pathway. Explore the current climate for biosimilars business including evaluation of the competitive landscape, reimbursement considerations and clinical development at our summit.
Topics in development include:
Scientific and technical challenges for the development of biosimilars
Business strategies to deal with competitive market entry
Update on FDA’s view of biosimilars
Biosimilars in emerging markets
(Photo courtesy of patentdocs.org)
Thursday, March 29, 2012 to Friday, March 30, 2012
Washington, D.C., U.S.A.
Contact: (cbireg@cbinet.com)
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
